Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Shettle Eye Research Inc

Neither a doctor nor a teaching hospital

Research payments

$617,021

20 payments

Through program year 2025, Shettle Eye Research Inc is reported as receiving $617,021 in research payments, across 20 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $8,084 2
2023 Research $18,645 3
2022 Research $323,591 2
2021 Research $122,724 1
2020 Research $31,880 3
2019 Research $112,097 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $524,521 4 payments
  2. Kala Pharmaceuticals, Inc. $50,600 7 payments
  3. Alcon Research LLC $18,899 3 payments
  4. Osmotica Pharmaceutical Corp. $14,918 4 payments
  5. AbbVie, Inc. $8,084 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Placebo-Controlled, Double-Masked, Multi-Center, Dose-Ranging Study to Evaluate the Safety, and Efficacy of Unr844 in Subjects With Presbyopia $446,061 3 payments
  2. Phase II Study Unr844 1.5% in Subjects With Presbyopia $78,460 1 payment
  3. Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease $50,600 7 payments
  4. A Multicenter, Open-Label Rocklatan Evaluation of Iop Lowering Efficacy and Safety As Replacement of Current Medical Therapy Regimen for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma Or Ocular Hypertension $10,725 2 payments
  5. Rvl-202 $9,003 2 payments
  6. A Multicenter, Open-Label Rocklatan (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% Evaluation of Iop Lowering Efficacy and Safety As Replacement of Current Medical Therapy Regimen for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma Or Ocular Hypertension $8,174 1 payment
  7. M23-730 - A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Tear Formulation with REFRESH OPTIVE Unit Dose in Patients with Dry Eye Disease $7,793 1 payment
  8. Rvl-203 $5,915 2 payments
  9. A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Tear Formulation with REFRESH OPTIVE Unit Dose in Patients with Dry Eye Disease $291 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record